China-based biotech BeiGene said company scientists and advisers will present 7 abstracts at the 106th Annual Meeting of the American Association for Cancer Research (AACR), which is being held in Philadelphia from April 18 to 22.
The company's abstract entitled "BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers" has been selected for oral presentation at the AACR Minisymposium "Exploiting the MAPK Pathway in Cancer" on Tuesday, April 21.
- here's the meeting notice from AACR
- and Abstract #4692, Abstract #669, Abstract #1651, Abstract #1653, Abstract #2589, Abstract #2597 and Abstract #5496